CN111407753A - 具有免疫疾病治疗效果的新型化合物及其应用 - Google Patents

具有免疫疾病治疗效果的新型化合物及其应用 Download PDF

Info

Publication number
CN111407753A
CN111407753A CN202010321725.6A CN202010321725A CN111407753A CN 111407753 A CN111407753 A CN 111407753A CN 202010321725 A CN202010321725 A CN 202010321725A CN 111407753 A CN111407753 A CN 111407753A
Authority
CN
China
Prior art keywords
cells
disease
present
diseases
immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010321725.6A
Other languages
English (en)
Chinese (zh)
Inventor
曹美罗
申東润
朴盛焕
梁哲宇
崔钟荣
朴潣廷
孙惠辰
李圣希
李善瑛
金恩敬
金在庚
李昇勋
朴星赫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Catholic University of Korea
Original Assignee
Catholic University of Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catholic University of Korea filed Critical Catholic University of Korea
Publication of CN111407753A publication Critical patent/CN111407753A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/18—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202010321725.6A 2014-04-29 2015-04-29 具有免疫疾病治疗效果的新型化合物及其应用 Pending CN111407753A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2014-0051261 2014-04-29
KR1020140051261 2014-04-29
CN201580021720.9A CN106458869A (zh) 2014-04-29 2015-04-29 具有免疫疾病治疗效果的新型化合物及其应用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580021720.9A Division CN106458869A (zh) 2014-04-29 2015-04-29 具有免疫疾病治疗效果的新型化合物及其应用

Publications (1)

Publication Number Publication Date
CN111407753A true CN111407753A (zh) 2020-07-14

Family

ID=54601170

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010321725.6A Pending CN111407753A (zh) 2014-04-29 2015-04-29 具有免疫疾病治疗效果的新型化合物及其应用
CN201580021720.9A Pending CN106458869A (zh) 2014-04-29 2015-04-29 具有免疫疾病治疗效果的新型化合物及其应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580021720.9A Pending CN106458869A (zh) 2014-04-29 2015-04-29 具有免疫疾病治疗效果的新型化合物及其应用

Country Status (8)

Country Link
US (2) US20170114008A1 (enExample)
EP (1) EP3130582B8 (enExample)
JP (1) JP6462002B2 (enExample)
KR (1) KR101705446B1 (enExample)
CN (2) CN111407753A (enExample)
AU (1) AU2015254037B2 (enExample)
CA (1) CA2946516C (enExample)
ES (1) ES2702337T3 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113907047A (zh) * 2021-12-13 2022-01-11 天津医科大学总医院空港医院 一种自身抗原表位诱导的eam小鼠模型的建立方法
WO2024001152A1 (zh) * 2022-06-28 2024-01-04 广东省人民医院 胶体锰佐剂在建立原发性干燥综合征动物模型中的应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3043785T3 (da) 2013-09-13 2021-11-15 Univ Chiba Nat Univ Corp Anvendelse af r-ketamin og salt deraf som lægemidler
KR101949451B1 (ko) 2015-10-13 2019-05-10 주식회사 이노파마스크린 염증성 장 질환 및 아토피 피부염 치료용 조성물
WO2018133139A1 (zh) 2017-01-21 2018-07-26 宁波知明生物科技有限公司 芍药苷-6'-o-苯磺酸酯在治疗干燥综合征的应用
US11370748B2 (en) 2017-09-05 2022-06-28 1Globe Biomedical Co., Ltd. Therapeutics for central nervous system disorders
WO2019160057A1 (ja) * 2018-02-15 2019-08-22 国立大学法人千葉大学 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物
AU2019334202A1 (en) 2018-09-06 2021-03-25 Innopharmascreen, Inc. Methods and compositions for treatment of asthma or parkinson's disease
KR102147802B1 (ko) 2018-11-07 2020-08-25 가톨릭대학교 산학협력단 신규 화합물 및 칼시뉴린 억제제를 포함하는 이식 거부 반응 또는 이식 거부 질환의 예방 및 치료용 조성물
US20220033489A1 (en) * 2018-12-04 2022-02-03 The Children's Medical Center Corporation Methods and compositions for treating asthma
KR102316961B1 (ko) * 2020-01-29 2021-10-26 프라비바이오 주식회사 면역억제제로서의 벤젠 유도체의 면역억제용 약학적 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110053941A1 (en) * 2007-11-30 2011-03-03 Newlink Genetics IDO Inhibitors
US20130095140A1 (en) * 2011-01-07 2013-04-18 Elcelyx Therapeutics, Inc. Biguanide Compositions and Methods of Treating Metabolic Disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4183956A (en) * 1975-11-05 1980-01-15 William H. Rorer, Inc. Method for treating gastrointestinal spasms, gastrointestinal hyperacidity and hypertensive disorders with amidinoureas
US4060635A (en) * 1975-03-31 1977-11-29 William H. Rorer, Inc. Amidinoureas for treating diarrhea
US8053477B2 (en) * 2002-03-29 2011-11-08 University Of Maryland, Baltimore Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the same
US7622117B2 (en) 2002-04-17 2009-11-24 Dynamis Therapeutics, Inc. 3-deoxyglucosone and skin
ES2586837T3 (es) * 2009-08-03 2016-10-19 University Of Miami Método para la expansión in vivo de linfocitos T reguladores
KR101136045B1 (ko) * 2009-11-16 2012-04-18 한국화학연구원 Ｎ1-(펜에틸)-ｎ2-치환된 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물
EP2522653A4 (en) * 2010-01-06 2013-06-12 Hanall Biopharma Co Ltd BIGUANIDE DERIVATIVE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE BIGUANIDE DERIVATIVE AS AN ACTIVE SUBSTANCE
US8809541B2 (en) 2010-08-25 2014-08-19 Neopharm Co., Ltd. Heterocyclic compound, and composition for treating inflammatory diseases using same
KR101432246B1 (ko) * 2011-09-20 2014-08-21 가톨릭대학교 산학협력단 메포민을 포함하는 자가면역질환 예방 및 치료용 조성물
CN102698266A (zh) * 2012-05-15 2012-10-03 中国医学科学院北京协和医院 Cd200在制备系统性红斑狼疮治疗药物中的应用
KR101432892B1 (ko) 2012-09-17 2014-08-21 가톨릭대학교 산학협력단 메트포민을 이용한 루프스를 포함하는 면역질환의 예방 또는 치료용 조성물
KR101613371B1 (ko) * 2014-11-10 2016-04-18 가톨릭대학교 산학협력단 면역질환 치료효과를 갖는 신규한 화합물 및 이의 용도

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110053941A1 (en) * 2007-11-30 2011-03-03 Newlink Genetics IDO Inhibitors
US20130095140A1 (en) * 2011-01-07 2013-04-18 Elcelyx Therapeutics, Inc. Biguanide Compositions and Methods of Treating Metabolic Disorders

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113907047A (zh) * 2021-12-13 2022-01-11 天津医科大学总医院空港医院 一种自身抗原表位诱导的eam小鼠模型的建立方法
WO2024001152A1 (zh) * 2022-06-28 2024-01-04 广东省人民医院 胶体锰佐剂在建立原发性干燥综合征动物模型中的应用

Also Published As

Publication number Publication date
US20170114008A1 (en) 2017-04-27
AU2015254037B2 (en) 2019-03-21
EP3130582B8 (en) 2019-01-02
US20180118668A1 (en) 2018-05-03
CN106458869A (zh) 2017-02-22
KR20150124923A (ko) 2015-11-06
EP3130582A1 (en) 2017-02-15
KR101705446B1 (ko) 2017-02-09
US10100006B2 (en) 2018-10-16
EP3130582B1 (en) 2018-10-10
CA2946516C (en) 2022-02-01
JP2017519723A (ja) 2017-07-20
CA2946516A1 (en) 2015-11-05
AU2015254037A1 (en) 2016-11-17
EP3130582A4 (en) 2017-08-30
JP6462002B2 (ja) 2019-01-30
ES2702337T3 (es) 2019-02-28

Similar Documents

Publication Publication Date Title
JP6462002B2 (ja) 免疫疾患治療効果を有する新規化合物およびその使用
US10716771B2 (en) Pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing biguanide derivative compound as active ingredient
Akazawa et al. Adjuvant-mediated tumor regression and tumor-specific cytotoxic response are impaired in MyD88-deficient mice
TW585915B (en) Methods for activating natural killer (NK) cells
JP2016515571A (ja) 調節性ｔ細胞への分化を誘導し、及び増殖を促進することにより免疫反応を抑制するための医薬組成物
KR101613371B1 (ko) 면역질환 치료효과를 갖는 신규한 화합물 및 이의 용도
JP2023134693A (ja) 人体抹消血液のＮＫ細胞より高い水準のＮＣＲ、細胞毒性及びＩＦＮ－γ生産能力を有するメモリ様ＮＫ細胞の製造方法
KR20130106320A (ko) 골수유래억제세포를 유효성분으로 포함하는 이식거부반응 또는 자가면역질환의 예방 또는 치료용 조성물
WO2015167243A1 (ko) 면역질환 치료효과를 갖는 신규한 화합물 및 이의 용도
KR20130106786A (ko) 골수유래억제세포 및 레바미피드를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
KR101273747B1 (ko) Ｓｔａ-21을 유효성분으로 함유하는 관절염의 예방 및 치료용 조성물
RU2597976C2 (ru) Способ получения регуляторных дендритных клеток
KR20170141914A (ko) 베르바민을 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
KR101627046B1 (ko) 메트포민, 코엔자임 q10 및 스타틴을 유효성분으로 포함하는 복합제제 및 이의 면역질환 치료를 위한 용도
KR20170051376A (ko) Foxp3를 발현하는 수지상 세포를 포함하는 면역 조절용 약학적 조성물
KR102366937B1 (ko) 3,3`-디인돌릴메탄을 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
HK40067371B (en) METHOD FOR PRODUCING MEMORY-LIKE NK CELLS WITH ABILITY TO EXPRESS HIGHER LEVELS OF NCRS, CYTOTOXICITY, AND IFN-γ THAN NK CELLS IN HUMAN PERIPHERAL BLOOD
HK40067371A (en) METHOD FOR PRODUCING MEMORY-LIKE NK CELLS WITH ABILITY TO EXPRESS HIGHER LEVELS OF NCRS, CYTOTOXICITY, AND IFN-γ THAN NK CELLS IN HUMAN PERIPHERAL BLOOD
KR100797049B1 (ko) 아토피성 피부염에 치료효과를 갖는 ｃｄ4 ｔ 세포
JPS591420A (ja) 糖鎖関連抗原およびその製造法
KR20160052220A (ko) 타크롤리무스 및 비타민d를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200714